DermTech, Inc. — Cyborg Score 1/10

Strategic Profile

The company focused on transforming dermatology diagnostics through molecular testing rather than traditional biopsy methods. Operations ceased following the bankruptcy filing, and the company now exists in liquidation status with its stock trading on OTC markets.

Cyborg Score Rationale

The company filed for Chapter 11 liquidation bankruptcy in August 2025 and is no longer operational. All business operations have ceased and the company is in liquidation proceedings.

Top Insights

• Filed Chapter 11 bankruptcy liquidation in August 2025
• Stock now trades OTC (DMTKQ) at penny stock prices ($0.01)
• Formerly developed non-invasive melanoma and skin disease diagnostics
• Business model focused on precision dermatology via skin genomics testing

Named Competitors

• Strata Skin Sciences — Dermatology diagnostics and treatments

Recent Developments

• (August 2025) Filed Chapter 11 liquidation bankruptcy
• Stock delisted from NASDAQ and now trades OTC

Open the full interactive DermTech, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.